News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Serentis Starts Phase II Trial with First-in-Class SRD441 for Eczema
April 7, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--Serentis, a privately owned biopharmaceutical company, announced today that it has commenced patient recruitment in a Phase II clinical trial for atopic dermatitis (AD), a type of eczema.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
Europe
MORE ON THIS TOPIC
Deals
Roche inks up to $2B deal with Atavistik for new cardiometabolic drugs
September 24, 2026
·
2 min read
·
Gabrielle Masson
IN PARTNERSHIP WITH CURIUM
How radioligand therapy is rewriting cancer care
September 24, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Job Trends
Growth mode: 3 biotechs that are staffing up after series B raises
September 24, 2026
·
3 min read
·
Angela Gabriel
Immunology and inflammation
Immunovant ditches lupus for multi-hyphenate inflammatory drug after mid-stage miss
September 23, 2026
·
2 min read
·
Annalee Armstrong
